[go: up one dir, main page]

WO1997024138A3 - Medical use of proteases - Google Patents

Medical use of proteases Download PDF

Info

Publication number
WO1997024138A3
WO1997024138A3 PCT/GB1996/003089 GB9603089W WO9724138A3 WO 1997024138 A3 WO1997024138 A3 WO 1997024138A3 GB 9603089 W GB9603089 W GB 9603089W WO 9724138 A3 WO9724138 A3 WO 9724138A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteases
medical use
pathways
modulators
intracellular signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/003089
Other languages
French (fr)
Other versions
WO1997024138A2 (en
Inventor
Tracey Leahanne Mynott
Christian Engwerda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortecs Ltd
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Priority to JP9524091A priority Critical patent/JP2000502697A/en
Priority to AU11818/97A priority patent/AU1181897A/en
Priority to EP96942449A priority patent/EP0876153A2/en
Publication of WO1997024138A2 publication Critical patent/WO1997024138A2/en
Publication of WO1997024138A3 publication Critical patent/WO1997024138A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Proteases have been found to be modulators of intracellular signal transduction, in particular modulators of pathways in which inositol phosphates play a role, and are therefore useful in the treatment of various diseases and conditions which are mediated by these intracellular signal pathways.
PCT/GB1996/003089 1995-12-29 1996-12-13 Medical use of proteases Ceased WO1997024138A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9524091A JP2000502697A (en) 1995-12-29 1996-12-13 Use of proteases in medicine
AU11818/97A AU1181897A (en) 1995-12-29 1996-12-13 Medical use of proteases
EP96942449A EP0876153A2 (en) 1995-12-29 1996-12-13 Medical use of proteases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526691.2A GB9526691D0 (en) 1995-12-29 1995-12-29 Medical use of proteases
GB9526691.2 1995-12-29

Publications (2)

Publication Number Publication Date
WO1997024138A2 WO1997024138A2 (en) 1997-07-10
WO1997024138A3 true WO1997024138A3 (en) 1997-10-16

Family

ID=10786186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003089 Ceased WO1997024138A2 (en) 1995-12-29 1996-12-13 Medical use of proteases

Country Status (6)

Country Link
EP (1) EP0876153A2 (en)
JP (1) JP2000502697A (en)
AU (1) AU1181897A (en)
GB (1) GB9526691D0 (en)
WO (1) WO1997024138A2 (en)
ZA (1) ZA9610433B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102253A1 (en) 1997-02-25 2002-08-01 Mynott Tracey Lehanne Component of bromelain
AU6303898A (en) 1997-02-25 1998-09-18 Cortecs (Uk) Limited Component of bromelain
DE19726255C2 (en) * 1997-06-20 2000-03-16 Mucos Pharma Gmbh & Co Influence of cytokines by proteolytic enzymes and rutoside
DE19726254C2 (en) * 1997-06-20 1999-10-21 Mucos Pharma Gmbh & Co Tolerance induction through proteases
DE19726244C2 (en) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Use of proteolytic enzymes and rutoside to prevent or treat graft rejection
RU2149021C1 (en) * 1998-05-07 2000-05-20 Научный центр акушерства, гинекологии и перинатологии РАМН Method of pharmacological treatment of autoimmune male sterility
DE19957318A1 (en) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Influence of TGF-beta by proteolytic enzymes
DE10018980A1 (en) * 2000-04-17 2001-11-08 Mucos Pharma Gmbh & Co Prophylaxis and therapy of diabetes mellitus I using proteolytic enzymes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000082A1 (en) * 1994-06-24 1996-01-04 Cortecs Limited Medical use of bromelain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000082A1 (en) * 1994-06-24 1996-01-04 Cortecs Limited Medical use of bromelain

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Systematische Enzymtherapie: Grosse Zukunft zu erwarten", THERAPIEWOCHE ÖSTERREICH, vol. 7, no. 2, 1992, pages 65 - 72, XP000652911 *
A.GESCHER: "Modulators of signal transduction as cancer chemotherapeutic agents - novel mechanisms and toxicities", TOXICOLOGY LETTERS, vol. 82/83, December 1995 (1995-12-01), pages 159 - 163, XP000652605 *
DARIO C. ALTIERI: "Proteases and protease receptors in modulation of leukocyte effector functions", J. LEUKOC. BIOL., vol. 58, no. 2, 1995, pages 120 - 127, XP000652620 *
DENIS GODIN ET AL.: "Mode of action of thrombin in the rat aorta", BR. J. PHARMACOL., vol. 115, no. 6, July 1995 (1995-07-01), pages 903 - 908, XP000652621 *
ELENA GABRIELESCU: "An integrative approach to the proteolytic control of the cell-mediated cytotoxicity", ROUM. ARCH. MICROBIOL. IMMUNOL., vol. 51, no. 1-2, 1992, pages 33 - 51, XP000652932 *
G.STAUDER: "Pharmacological effects of oral enzyme combinations", CASOPIS LEKARU CESKYCH, vol. 134, no. 19, 1995, pages 620 - 624, XP000652595 *
M.T.ALONSO ET AL.: "Leupeptin does not affect the normal signal transduction mechanism in platelets", FEBS LETT., vol. 244, no. 2, 1989, pages 407 - 410, XP000652613 *

Also Published As

Publication number Publication date
AU1181897A (en) 1997-07-28
GB9526691D0 (en) 1996-02-28
JP2000502697A (en) 2000-03-07
EP0876153A2 (en) 1998-11-11
WO1997024138A2 (en) 1997-07-10
ZA9610433B (en) 1998-06-11

Similar Documents

Publication Publication Date Title
AU635961B2 (en) Novel peptidase and isomerase inhibitors
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
AU7623096A (en) Use of epinastine in the treatment of pain
DE69626539D1 (en) topical use of vitamin D for the treatment of eye diseases
NO965564L (en) Medical application of bromelain
AU5967896A (en) Peptidyl heterocycles useful in the treatment of thrombin re lated disorders
AU7833194A (en) Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
WO1997024138A3 (en) Medical use of proteases
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU4704797A (en) Use of benzopyranols to treat neurological disorders
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
WO2000061231A3 (en) Medical use
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU1867297A (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
AU6147296A (en) Therapeutic use of acetazolamide for the treatment of brain edema
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
AU3242293A (en) Diagnosis of hereditary retinal degenerative diseases
EP0784983A3 (en) Use of extracellular hemoglobin
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
AU7351594A (en) Disposable toe band
AU2233495A (en) Treatment or diagnosis of abnormal signal transduction disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

WWE Wipo information: entry into national phase

Ref document number: 1996942449

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996942449

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996942449

Country of ref document: EP